Company / Working Capital
CytomX Therapeutics, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$97.3M
FY2025
5-year range
$21.5M / $204.0M
FY2021-FY2025
Trend
+351.9%
vs FY2024
Sector context
#195 of 213
Health Care
What the data says
Working Capital changed +352% YoY in FY2025, a notable deviation from the 9-year average annual change of +31%.
Based on SEC 10-K filings.
$97M in FY2025 with a 5-year CAGR of -15.3%.
Improved from $27M to $97M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +4.8%
- 5-Year CAGR
- -15.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 213This company $97.3M Sector average $934.6M
▼
-89.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -15.3%, indicating a declining trend.
- In FY2025, working capital increased 351.9% year-over-year.
- Ranks #195 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $97.3M | +351.9% |
| FY2024 | $21.5M | -20.3% |
| FY2023 | $27.0M | -68.0% |
| FY2022 | $84.5M | -58.6% |
| FY2021 | $204.0M | -8.6% |
| FY2020 | $223.1M | +2.5% |
| FY2019 | $217.7M | -37.4% |
| FY2018 | $347.6M | +6.1% |
| FY2017 | $327.5M | +114.9% |
| FY2016 | $152.4M | -12.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026